Polycythaemia vera: molecular genetics, diagnostics and therapeutics

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Polycythaemia vera (PV) is a myeloproliferative neoplasm characterized by excessive red blood cell production.
• PV is associated with specific genetic mutations, notably JAK2 V617F, impacting disease pathogenesis.
• Understanding the genetic landscape and immunological factors is crucial for comprehending PV progression.

Purpose of the Study:

• To provide a comprehensive overview of Polycythaemia vera, integrating genetic, immunological, and clinical aspects.
• To discuss diagnostic criteria, differential diagnoses, and management strategies for PV.
• To explore therapeutic approaches, including phlebotomy and chemo-cytoreductive therapy, and drug resistance.

Main Methods:

• Review of genetic mutations (JAK2 V617F) and their role in PV.
• Analysis of immunological concepts (allele burden, mutation timing, onco-inflammation) in disease progression.
• Examination of World Health Organization diagnostic criteria and differential diagnoses.
• Overview of phlebotomy (erythrocytapheresis) procedures and chemo-cytoreductive therapy.

Main Results:

• The JAK2 V617F mutation is a common driver in PV and other myeloproliferative neoplasms.
• Genetic factors and immunological responses influence disease severity and transformation risk.
• Phlebotomy and chemo-cytoreductive therapy are key management strategies for risk stratification and complication prevention.
• Strategies for managing drug resistance are essential for long-term patient care.

Conclusions:

• PV management requires a multi-faceted approach, integrating genetic insights with clinical practice.
• Accurate diagnosis, risk stratification, and tailored therapy are vital for optimizing outcomes in PV patients.
• Continued research into novel drug designs and resistance mechanisms is necessary to improve treatment efficacy.